Alnylam Pharmaceuticals, Inc. (ALNY)
| Previous close | 147.70 |
| Open | 146.37 |
| Bid | 147.06 x 100 |
| Ask | 147.55 x 100 |
| Day's range | 146.01 - 148.44 |
| 52-week range | 143.52 - 218.88 |
| Volume | |
| Avg. volume | 853,954 |
| Market cap | 18.633B |
| Beta (5Y monthly) | 0.40 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -3.52 |
| Earnings date | 02 May 2024 - 06 May 2024 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 222.68 |
ZacksWhy Alnylam Pharmaceuticals (ALNY) Stock Might be a Great Pick
Alnylam Pharmaceuticals (ALNY) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.
Business WireAlnylam Presents Positive Results from the KARDIA-2 Phase 2 Study of Zilebesiran Added to Standard of Care Antihypertensives in Patients with Inadequately Controlled Hypertension
CAMBRIDGE, Mass., April 07, 2024--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced positive results from the KARDIA-2 Phase 2 study evaluating the efficacy and safety of a single subcutaneous dose of zilebesiran when added to one of three standard of care antihypertensives including a thiazide-like diuretic (indapamide), calcium channel blocker (amlodipine) or angiotensin receptor blocker (olmesartan). Zilebesiran is an investigational RNAi the
Simply Wall St.Those who invested in Alnylam Pharmaceuticals (NASDAQ:ALNY) five years ago are up 63%
It hasn't been the best quarter for Alnylam Pharmaceuticals, Inc. ( NASDAQ:ALNY ) shareholders, since the share price...
